FGP
EWTX icon

Freestone Grove Partners’s Edgewise Therapeutics EWTX Stock Holding History

Freestone Grove Partners’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.68M Buy
+148,426
New +$4.28M 0.03% 326

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Freestone Grove Partners's EWTX Position: Q1 2026 in Review

Freestone Grove Partners opened a new position in Edgewise Therapeutics (EWTX) in Q1 2026: 148,426 shares worth $4.68M. The stake represents 0.03% of the portfolio and ranks #326 among its holdings.

214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Freestone Grove Partners held 148,426 shares of Edgewise Therapeutics worth $4.68M as of Q1 2026.
  • Edgewise Therapeutics was a new Freestone Grove Partners position in Q1 2026.
  • Edgewise Therapeutics made up 0.03% of Freestone Grove Partners's portfolio in Q1 2026, its #326 holding.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.